What's in Greenwich LifeSciences, Inc.'s pipeline?

Greenwich LifeSciences, Inc. has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Greenwich LifeSciences, Inc.'s portfolio?

Top competitors by shared drug class: NovaRx Corporation, PT. JES Kasih Nusantara Sejahterah.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/greenwich-lifesciences-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Greenwich LifeSciences, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Greenwich LifeSciences, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
GLSI-100	GLSI-100	phase 3	Dendritic cell vaccine	HER2 and other tumor-associated antigens	Oncology

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

NovaRx Corporation · 1 shared drug class
PT. JES Kasih Nusantara Sejahterah · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Greenwich LifeSciences, Inc.:

Cite this brief

Drug Landscape (2026). Greenwich LifeSciences, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/greenwich-lifesciences-inc. Accessed 2026-05-17.